TickerTalks
Browse all tickers →
TickerTalks›$NVCR
NVNVCR

Novocure Ltd

$NVCR·$2.0B·Medical - Devices·Healthcare
$16.31-4.2%YTD+29.2%1Y+46.3%
Mentions · last 7 days
2026-07-20: 0 posts2026-07-21: 2 posts2026-07-22: 9 posts2026-07-23: 145 posts2026-07-24: 23 posts2026-07-25: 2 posts2026-07-26: 7 posts188+1%
Price updated 10m ago·X counts updated 2d ago
NVNVCR
$NVCRNovocure Ltd
$16.31-4.23%188 posts+1%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $NVCR, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Driven by hypeAcceleratingAI verdict · as of 2026-07-28

The move is getting stronger, with heavier trading behind it.

Tumor-treating fields (TTFields) maker just delivered a huge Q2 and raised guide — 24-28% pop and momentum is real.

Novocure develops Tumor Treating Fields (TTFields) therapy — a non-invasive electric-field treatment for solid tumors, currently approved for glioblastoma, pleural mesothelioma, and increasingly other indications. The stock is up 46% TTM and Q2 delivered the breakout the bulls have been waiting for.

  • The Q2 print was clean and above the whisper: revenue of $183.6M versus $172.7M estimate (up 16% YoY), EPS of -$0.13 versus -$0.33 estimate (huge beat), and gross margin expanded to 78% from 74% YoY — this is the shape of a business hitting scale.
  • The FY26 guide is what triggered the +24-28% pop: management raised sales guidance to $710-725M, which implies breakeven finish to the year — that's the sort of guide-through that makes the equity mechanically re-rate to a growth-plus-profitability multiple rather than an unprofitable-biotech multiple.
  • Technicals confirm the momentum: sniper MA flipping green and RSI back above 50 on the daily are the standard technical setup for continued momentum — position at 62% of the 52-week range means there's more room before the tape gets extended.
  • The pipeline expansion is the durable driver: TTFields for lung cancer and ovarian cancer are in trials, and if either reads out positive, Novocure has genuine platform-expansion optionality that could support the current market cap even if glioblastoma revenue plateaus.

The October 29 Q3 print is the next real datapoint — TTFields revenue by indication, gross-margin trajectory, and any commentary on lung and ovarian trial progress matter more than the EPS number. What would break the setup: a Q3 revenue miss combined with a walkback on the $710-725M guide, since the +24-28% pop assumes the breakeven-finish trajectory holds through the year.

Agrees with X sentimentThe bullish framing around the Q2 revenue beat, EPS beat, gross-margin expansion, raised guide, and the sniper MA / RSI technical confirmation matches the actual print and price action — this is a case where the sentiment tracks the fundamental inflection cleanly.

What to watch: The Oct 29 Q3 print — TTFields revenue by indication, gross-margin trajectory, and any commentary on lung and ovarian trial progress matter more than the EPS. What would break the setup: a Q3 revenue miss combined with a walkback on the $710-725M guide, since the +24-28% pop assumes the breakeven-finish trajectory holds through the year.

On the calendar: 2026-10-29 — Q3 2026 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment7 posts analyzed · as of 2026-07-27

Novocure delivered a strong Q2 with revenue of $183.6M versus $172.7M estimate up 16% YoY, EPS -$0.13 versus -$0.33 estimate, and gross margin 78% versus 74% YoY. The stock popped 24-28% after raised 2026 sales guidance to $710-725M implying breakeven finish. Sniper MA flipped green and RSI back above 50 on the daily.

Read the AI verdict + X sentiment for $NVCR

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Devices sits in its cycle right now — and what that implies for $NVCR.

Medical - Devices · Healthcare

No material change from last week — ISRG's da Vinci 5 procedure growth (+23%) confirms surgical robotics has transitioned from premium to standard-of-care in major procedures.

Industry benchmark

18-name peer basket
-11.4%YTD
-6.7%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-15.4How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
115%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-22.1%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-1.1%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
3.3Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-44.0%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
76.1%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.3Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Jul 23, 2026$-0.13$-0.33+60.8%
Q1 2026Apr 30, 2026$-0.62$-0.51-21.0%
Q4 2025Feb 26, 2026$-0.22$-0.41+46.3%
Q3 2025Oct 30, 2025$-0.33$-0.42+21.4%
Next earningsThu, Oct 29·consensus EPS $-0.24

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$183.6M+15.6%77.6%-5.8%$-0.13$5.3M
Q1 FY26$174.1M+12.3%77.6%-38.7%$-0.62$-18.7M
Q4 FY25$174.3M+8.1%75.8%-23.2%$-0.22$-22.9M
Q3 FY25$167.2M+7.8%73.2%-21.5%$-0.33$14.9M

Forward consensus

5-year forecast · up to 6 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$708.7M$693.2M – $733.1M-$1.57-$1.81 – -$1.306
FY27$796.4M$749.8M – $887.4M-$1.04-$1.41 – -$0.146
FY28$932.0M$849.4M – $1.0B-$0.55-$1.11 – $0.455
FY29$1.5B$1.4B – $1.6B$1.95$1.84 – $2.182
FY30$1.7B$1.7B – $1.9B$4.15$3.91 – $4.632

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.9×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.62%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+2.0%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+23.8%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 95.8M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.9% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.945-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellJun 4Frank X LeonardCEO34.3K sh$615KSellJun 2David HungDirector2.9K sh$46KSellJun 2Gabriel LeungDirector2.9K sh$46KSellJun 2Kristin StaffordDirector2.9K sh$46KSellJun 2Allyson J OceanDirector2.9K sh$46KSellJun 2Timothy J ScannellDirector2.9K sh$46KSellJun 2Jeryl L HillemanDirector2.9K sh$46KSellJun 2Vernon W AnthonyDirector2.9K sh$46KSellMar 5Mukund ParavasthuCOO43.2K sh$596KSellMar 4Nicolas LeupinFormer Chief Medical Officer1.1K sh$15K
1–10 of 15
+ 20 other (18 awards · 1 exempt · 1 inkind) in window

See when $NVCR insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KPress release / Reg FDJun 308-K — Item 7.01: Press release / Reg FD
AI summary

NVCR filed an 8-K under Reg FD (Item 7.01), disclosing material non-public information simultaneously to all investors. The disclosure covers: announcing that that that Optune Pax® has received a CE (Conformité Européenne) Mark for the treatment of adult patients with locally-advanced pancreatic cancer of exocrine origin, concomitant with gemcitabine and nab-paclitaxel (gem/nab-pac) in accordance with guideline recommendations. This is typically an investor presentation, conference slides, or press release furnished as an exhibit. Reg FD filings ensure equal access to information for all investors; the substantive data is in the attached exhibit.

8-KPress release / Reg FDJun 188-K — Item 7.01: Press release / Reg FD
AI summary

NVCR filed an 8-K under Reg FD (Item 7.01), disclosing material non-public information simultaneously to all investors. The disclosure covers: announcing top line results from its Phase 3 TRIDENT trial, which evaluated the initiation of Tumor Treating Fields (TTFields) therapy for newly diagnosed glioblastoma (GBM) at the start of chemoradiation (Early Start Arm) compared to initiating TTFields therapy during the subsequent maintenance phase of treatment (Maintenance Start Arm). This is typically an investor presentation, conference slides, or press release furnished as an exhibit. Reg FD filings ensure equal access to information for all investors; the substantive data is in the attached exhibit.

8-KOfficer or director changeJun 58-K — Item 5.02: Officer or director change · Item 5.07: Shareholder vote
AI summary

NVCR filed an 8-K under Item 5.07 reporting vote results from a stockholder meeting. Annual Meeting”).. This is a routine proxy results filing; investors should check for any failed proposals that could signal governance concerns. Also covers Item(s) 5.02.

8-K/AOfficer or director change (amended)Apr 248-K/A — Item 5.02: Officer or director change
8-KOfficer or director changeApr 98-K — Item 5.02: Officer or director change
8-KPress release / Reg FDMar 268-K — Item 7.01: Press release / Reg FD
8-KPress release / Reg FDFeb 248-K — Item 7.01: Press release / Reg FD
8-KPress release / Reg FDFeb 118-K — Item 7.01: Press release / Reg FD
+ 15 other (4 13Gs · 3 earnings 8-Ks · 3 proxys · 2 10-Qs) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

NovoCure (NVCR) Upgraded to Buy: What Does It Mean for the Stock?zacks.com·1d agoWall Street Analysts Believe NovoCure (NVCR) Could Rally 46.63%: Here's is How to Tradezacks.com·1d agoUnlocking NovoCure (NVCR) International Revenues: Trends, Surprises, and Prospectszacks.com·1d agoNovoCure: Why I'm Fading The Q2 Earnings Rallyseekingalpha.com·4d agoNovoCure's Clean Beat Signals A Shift Toward Profitability (Rating Upgrade)seekingalpha.com·4d ago

More in Medical - Devices

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$ISRG$MDT$BIO$TMDX$BSX$EW$ABT$BFLY
Voices on X · top 7 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport